Protalix BioTherapeutics
PLX
63 hedge funds and large institutions have $17.6M invested in Protalix BioTherapeutics in 2025 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 20 increasing their positions, 3 reducing their positions, and 30 closing their positions.
567% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 3
553% more call options, than puts
Call options by funds: $379K | Put options by funds: $58K
59% more capital inflows, than outflows
Capital inflows: $16M | Capital outflows: $10.1M
4.47% more ownership
Funds ownership: 10.49% → 14.96% (+4.5%)
0% more funds holding
Funds holding: 63 → 63 (0)
0% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.37M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.69M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$992K |
| 4 |
State Street
Boston,
Massachusetts
|
+$909K |
| 5 |
Renaissance Technologies
New York
|
+$872K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.47M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$1.57M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.15M |
| 4 |
Jane Street
New York
|
-$753K |
| 5 |
GSA Capital Partners
London,
United Kingdom
|
-$536K |
PLX Hedge Fund Activity: Q2 2025 in Review
63 of the 7,623 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2025, worth a combined $17.6M — down 16% from $21M a quarter earlier.
Fund positioning in PLX was balanced in Q2 2025: 30 funds opened new positions, 30 closed out, 20 added to existing stakes and 3 trimmed.
The largest buyer was BlackRock, adding an estimated $6.37M. The largest seller was Millennium Management, exiting entirely with an estimated $2.47M sold.
- 63 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $17.6M of Protalix BioTherapeutics stock for Q2 2025, down 16% quarter-over-quarter.
- 30 funds opened new Protalix BioTherapeutics positions in Q2 2025 and 30 closed out, a net change of 0 holders.
- The largest Protalix BioTherapeutics buyer in Q2 2025 was BlackRock, an estimated $6.37M added.
- The largest Protalix BioTherapeutics seller in Q2 2025 was Millennium Management, an estimated $2.47M sold.
Based on aggregated 13F filings for Q2 2025.